• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by PureTech Health plc

    5/11/26 3:05:05 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRTC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    PureTech Health plc

    (Name of Issuer)


    Ordinary Shares

    (Title of Class of Securities)




    G7297M101

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    G7297M101


    1Names of Reporting Persons

    CITIGROUP INC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    14,636,273.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    14,636,273.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,636,273.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP Number(s):
    G7297M101


    1Names of Reporting Persons

    Citigroup Global Markets Holdings Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    14,636,273.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    14,636,273.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,636,273.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP Number(s):
    G7297M101


    1Names of Reporting Persons

    Citigroup Financial Products Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    14,636,273.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    14,636,273.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,636,273.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP Number(s):
    G7297M101


    1Names of Reporting Persons

    Citigroup Global Markets Holdings Bahamas Ltd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BAHAMAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    14,636,273.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    14,636,273.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,636,273.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP Number(s):
    G7297M101


    1Names of Reporting Persons

    Citigroup Global Markets Ltd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    14,636,273.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    14,636,273.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,636,273.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.0 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PureTech Health plc
    (b)Address of issuer's principal executive offices:

    6 TIDE STREET, SUITE 400, BOSTON, MASSACHUSETTS, 02210.
    Item 2. 
    (a)Name of person filing:

    Citigroup Global Markets Limited ("CGML"), Citigroup Global Markets Holdings Bahamas Limited ("CGMHBL"), Citigroup Financial Products Inc. ("CFP"), Citigroup Global Markets Holdings Inc. ("CGM Holdings"), Citigroup Inc. ("Citigroup").
    (b)Address or principal business office or, if none, residence:

    CGML: 25 Canada Square, London E14 5LB, United Kingdom. CGMHBL: Ocean Center, Montagu Foreshore, East Bay Street Nassau, New Providence Bahamas 19084. CFP, CGM Holdings and Citigroup: 388 Greenwich Street, New York, NY 10013.
    (c)Citizenship:

    CGML is chartered and headquartered in England. CGMHBL is chartered and headquartered in the Bahamas. CGM Holdings is a New York corporation. CFP and Citigroup are Delaware corporations.
    (d)Title of class of securities:

    Ordinary Shares
    (e)CUSIP No.:

    G7297M101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Foreign Financial Institution
    Item 4.Ownership
    (a)Amount beneficially owned:

    14,636,273
    (b)Percent of class:

    6.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    14,636,273

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    14,636,273

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    CGMHBL is the sole stockholder of CGML. CFP is the sole stockholder of CGMHBL. CGM Holdings is the sole stockholder of CFP. Citigroup is the sole stockholder of CGM Holdings.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Foreign Financial Institution is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    CITIGROUP INC
     
    Signature:Ruth M Clark
    Name/Title:Vice President
    Date:05/11/2026
     
    Citigroup Global Markets Holdings Inc.
     
    Signature:Ruth M Clark
    Name/Title:Vice President
    Date:05/11/2026
     
    Citigroup Financial Products Inc.
     
    Signature:Ruth M Clark
    Name/Title:Vice President
    Date:05/11/2026
     
    Citigroup Global Markets Holdings Bahamas Ltd
     
    Signature:David Graham
    Name/Title:UK Corporate Chain Controller
    Date:05/11/2026
     
    Citigroup Global Markets Ltd
     
    Signature:Simon Cumming
    Name/Title:Assistant Company Secretary
    Date:05/11/2026
    Get the next $PRTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRTC

    DatePrice TargetRatingAnalyst
    9/9/2024$58.00 → $45.00Outperform
    Leerink Partners
    1/7/2022$76.00 → $70.00Outperform
    SVB Leerink
    8/25/2021$74.00 → $76.00Outperform
    SVB Leerink
    More analyst ratings

    $PRTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Puretech Health Plc converted options into 16,382,534 shares (SEC Form 4)

    4 - PureTech Health plc (0001782999) (Reporting)

    5/6/26 7:38:15 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Puretech Health Plc claimed ownership of 302,479 shares (SEC Form 3)

    3 - PureTech Health plc (0001782999) (Reporting)

    4/30/26 9:35:10 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference

    Presentations to highlight differentiated approach to advancing deupirfenidone, reinforcing its potential to serve as a new standard of care within the evolving idiopathic pulmonary fibrosis treatment landscape PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced presentations showcasing its deupirfenidone (LYT-100) program at the upcoming American Thoracic Society (ATS) International Conference, taking place in Orlando, Florida, from May 15-20, 2026. Deupirfenidone is an investigational therapy being advanced by PureTech's Founded Ent

    5/13/26 7:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Announces Annual Results for Year Ended December 31, 2025

    Refined strategy and disciplined execution position Company to unlock value from its portfolio, which includes Celea Therapeutics' Phase 3-ready deupirfenidone for idiopathic pulmonary fibrosis, Gallop Oncology's clinically-validated LYT-200 for myeloid malignancies, and Seaport Therapeutics' advancing clinical-stage pipeline for neuropsychiatric disorders PureTech level cash, cash equivalents and short-term investments of $277.1 million1 and Consolidated cash, cash equivalents and short-term investments of $277.3 million1 as of December 31, 2025; Operational runway at least through the end of 2028, inclusive of the Company's expected participation in Founded Entity fundraisings As of M

    4/29/26 2:01:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange

    PureTech to maintain its primary listing on the London Stock Exchange Simplification of listing structure expected to enhance operational efficiency and focus resources on advancing the Company's portfolio PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that it has notified The Nasdaq Stock Market LLC ("Nasdaq") of its intention to voluntarily delist its American Depositary Shares ("ADSs"), each representing the right to receive ten (10) ordinary shares of the Company. Following the effectiveness of the delisting, PureTech's ord

    4/29/26 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    SEC Filings

    View All

    SEC Form F-6 POS filed by PureTech Health plc

    F-6 POS - PureTech Health plc (0001782999) (Subject)

    5/22/26 12:21:26 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by PureTech Health plc

    424B3 - PureTech Health plc (0001782999) (Filer)

    5/21/26 10:31:31 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 15F-12B filed by PureTech Health plc

    15F-12B - PureTech Health plc (0001782999) (Filer)

    5/21/26 8:32:06 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners resumed coverage on PureTech Health plc with a new price target

    Leerink Partners resumed coverage of PureTech Health plc with a rating of Outperform and set a new price target of $45.00 from $58.00 previously

    9/9/24 7:42:36 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink reiterated coverage on PureTech Health with a new price target

    SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $70.00 from $76.00 previously

    1/7/22 4:34:06 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink reiterated coverage on PureTech Health with a new price target

    SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $76.00 from $74.00 previously

    8/25/21 4:40:14 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Leadership Updates

    Live Leadership Updates

    View All

    PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced the appointment of Dr. Sharon Mates to its Board of Directors. Dr. Mates served as the Co-Founder, Chairman, and Chief Executive Officer of Intra-Cellular Therapies, Inc. from inception of the company in June 2002 until its acquisition by Johnson & Johnson (J&J) in 2025 for approximately $14.6 billion. She has decades of experience in neuropsychiatry, guiding a company she founded through successful commercialization and a major st

    4/27/26 7:05:00 AM ET
    $BNTC
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Appoints Robert Lyne as Chief Executive Officer

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announces that the Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO), and as a member of the Board of Directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217152848/en/Robert Lyne, Chief Executive Officer of PureTech Robert Lyne commented: "I'm honored to lead PureTech as CEO at such an important moment in its evolution. Over the past two years, I've seen first-hand the streng

    12/18/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Announces Leadership Transition

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces that Bharatt Chowrira, PhD, JD, has stepped down today from his role as Chief Executive Officer (CEO) and as a member of the Board of Directors. The Board of Directors has appointed Robert Lyne as Interim CEO with effect from today. Mr. Lyne joined PureTech as Chief Portfolio Officer in January 2024 and is an experienced leader of UK-listed life science innovation and venture capital companies, having previously served as CEO of Arix Bioscience plc. He will continue to work closely with PureTe

    7/16/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Financials

    Live finance-specific insights

    View All

    PureTech Health: Notice of Results

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2025, on Wednesday, April 29, 2026. A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D mo

    4/13/26 2:05:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Health: Notice of Half-Yearly Results

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended June 30, 2025, on Thursday, August 28, 2025. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep port

    8/18/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Health: Notice of Results

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2024, on Wednesday, April 30, 2025. A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a b

    4/23/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PureTech Health plc

    SC 13G - PureTech Health plc (0001782999) (Subject)

    11/12/24 1:29:13 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PureTech Health plc

    SC 13G/A - PureTech Health plc (0001782999) (Subject)

    11/7/24 9:47:57 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by PureTech Health plc (Amendment)

    SC 13G/A - PureTech Health plc (0001782999) (Subject)

    2/12/24 4:48:30 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care